$CBIO looks like it has potential to make a large move soon, Also it's #4 in list of top Fintel Gamma Squeeze list📈
Hi, today we are going to talk about Catalyst Biosciences and its current landscape. Catalyst Biosciences is poised to receive increasing attention from the market as relevant events are taking place. The clinical-stage biopharmaceutical company has been soaring over the announcement that the company entered into a global science collaboration agreement with...
Way over sold. Potential short squeeze coming
New and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it. Increased quarterly earnings growth. Low floater Resistance at at 3.00 range due to the preferred shares being exercisible at...
CBIO seems forming a very nice fallen angel formation. It has history of sharp breakout, and at this time it seems getting ready for another breakout. We are looking for a quick day trade if it breaks above $4.70 * Trade Criteria * Date First Found- June 29, 2017 Pattern/Why- Fallen angel formation Entry Target Criteria- Break of $4.70 Exit Target Criteria-...
U.S. Government Required Disclaimer - Commodity Futures Trading Commission Futures, Stocks and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation...
$CBIO Recent Highlights and Upcoming Milestones Recent Highlights: Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe Contract revenue for the three months ended March 31, 2017 was $0.3 million, compared with $0.1 million for the prior year period. The increase in contract revenue was due to the milestone revenue from ISU Abxis...